Related references
Note: Only part of the references are listed.Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
Tamara Perez-Jeldres et al.
INFLAMMATORY BOWEL DISEASES (2019)
Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study
G. D'Haens et al.
JOURNAL OF CROHNS & COLITIS (2019)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
Kunio Sugahara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease
Yun Qiu et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects
Tomohiko Harada et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2016)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2016)
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Experimental Models of Inflammatory Bowel Diseases
Patricia Kiesler et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2015)
Second generation S1P pathway modulators: Research strategies and clinical developments
Marc Bigaud et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2014)
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
Christopher Ma et al.
JOURNAL OF CROHNS & COLITIS (2014)
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
Ralf Gold et al.
JOURNAL OF NEUROLOGY (2014)
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor
Daniel J. Buzard et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis
Kenji Chiba et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Intestinal Effector T Cells in Health and Disease
Craig L. Maynard et al.
IMMUNITY (2009)
β-Arrestin Recruitment Assay for the Identification of Agonists of the Sphingosine 1-Phosphate Receptor EDG1
Miranda M. C. Van der Lee et al.
JOURNAL OF BIOMOLECULAR SCREENING (2008)
A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice
Jinghai Song et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology
Daniel C. Baumgart et al.
LANCET (2007)
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes
M Forrest et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Inflammatory bowel disease: the role of environmental factors
S Danese et al.
AUTOIMMUNITY REVIEWS (2004)
Cutting edge:: Cure of colitis by CD4+ CD25+ regulatory T cells
C Mottet et al.
JOURNAL OF IMMUNOLOGY (2003)
Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis
T Totsuka et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Advances in immunology: T-cell function and migration - Two sides of the same coin
UH von Andrian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions
ZJ Liu et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
